title: Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials.
abstract: OBJECTIVE
  To compare antimüllerian hormone (AMH) and antral follicle count (AFC) as predictors of ovarian response to controlled ovarian stimulation at individual fertility clinics.
  
  
  METHODS
  Retrospective analysis of individual study center data in two multicenter trials. Centers that provided >10 patients were included in the analysis.
  
  
  METHODS
  A total of 19 (n = 519 patients) and 18 study centers (n = 686 patients) participating in a long GnRH agonist trial (MERIT) and a GnRH antagonist trial (MEGASET), respectively.
  
  
  METHODS
  Infertile women of good prognosis.
  
  
  METHODS
  Long GnRH agonist or GnRH antagonist cycles.
  
  
  METHODS
  Correlation between AMH and AFC, and oocyte yield by each study center for each trial.
  
  
  RESULTS
  Antimüllerian hormone was more strongly correlated with oocyte yield than AFC: r = 0.56 vs. r = 0.28 in the GnRH agonist cohort, and r = 0.55 vs. r = 0.33 in the GnRH antagonist cohort. The correlation was numerically higher for AMH than for AFC at a significantly higher proportion of study centers: 17 (89%) and 15 (83%) centers in the long GnRH agonist and GnRH antagonist trial, respectively. Assessment of the relative capacity of AMH and AFC for predicting oocyte yield demonstrated that AMH dominated the model: AMH, R(2) = 0.29 and 0.23; AFC: R(2) = 0.07 and 0.07; AMH + AFC: R(2) = 0.30 and 0.23 for long GnRH agonist and GnRH antagonist trials, respectively.
  
  
  CONCLUSIONS
  Antimüllerian hormone was a stronger predictor of ovarian response to gonadotropin therapy than AFC at the study center level in both randomized trials utilizing GnRH agonist and GnRH antagonist protocols. Antral follicle count provided no added predictive value beyond AMH.
authors.affiliation: School of Medicine, University of Glasgow, Glasgow, United Kingdom.
authors.forename: Scott M
authors.initials: SM
authors.lastname: Nelson
authors.affiliation: Global Biometrics, Ferring Pharmaceuticals, Copenhagen, Denmark.
authors.forename: Bjarke M
authors.initials: BM
authors.lastname: Klein
authors.affiliation: Reproductive Health, Ferring Pharmaceuticals A/S, Copenhagen, Denmark. Electronic address: jca@ferring.com.
authors.forename: Joan-Carles
authors.initials: JC
authors.lastname: Arce
mesh_terms: D000328:Adult; D000554:Ambulatory Care Facilities / Q000706:statistics & numerical data; D054304:Anti-Mullerian Hormone / Q000097:blood*; D002452:Cell Count; D005260:Female; D006801:Humans; D007246:Infertility / Q000097:blood / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D054315:Oocyte Retrieval / Q000706:statistics & numerical data; D006080:Ovarian Follicle / Q000166:cytology*; D065851:Ovarian Reserve; D010062:Ovulation Induction / Q000706:statistics & numerical data; D011247:Pregnancy; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D054304:Anti-Mullerian Hormone
keywords: Antimüllerian hormone; IVF clinic; antral follicle count; multicenter randomized controlled trial; ovarian response